Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
摩根士丹利将Silence Therapeutics的目标股价从29美元上调至45美元，称第四季度显示 “有意义的进展”，维持增持评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册